Maxim downgraded Theriva Biologics (TOVX) to Hold from Buy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOVX:
- Theriva Biologics prices 6.8M shares at $1.10 in public offering
- Theriva Biologics announces primary endpoints for efficacy met in VIRAGE study
- Theriva Biologics Announces Positive VIRAGE Phase 2b Results
- Theriva Biologics Reports Positive VIRAGE Phase 2b Results
- Theriva Biologics says IDMC considers VCN-01 to be well tolerated
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue